Ecthyma gangrenosum complicating mogamulizumab treatment of Sézary syndrome

Ann Dermatol Venereol. 2021 Mar;148(1):63-65. doi: 10.1016/j.annder.2020.09.576. Epub 2021 Jan 16.

Authors

M Barré¹, A Valois¹, I Okhremchuk², M Sair¹, J Masbou¹, S Abed¹, T Boye¹, J-J Morand³

Affiliations

¹ Service de Dermatologie, HIA Sainte-Anne, Toulon, France.
² Service d'Anatomo-Pathologie, HIA Sainte-Anne, Toulon, France.
³ Service de Dermatologie, HIA Sainte-Anne, Toulon, France. Electronic address: morandjj@aol.com.

PMID: 33461792
DOI: 10.1016/j.annder.2020.09.576

No abstract available

Keywords: Ecthyma gangrenosum; Mogamulizumab; Sézary syndrome; Tumor necrosis.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Ecthyma* / drug therapy
Humans
Pseudomonas Infections*

Substances

Antibodies, Monoclonal, Humanized
mogamulizumab